U.S. markets open in 3 hours 37 minutes
  • S&P Futures

    3,304.00
    -29.75 (-0.89%)
     
  • Dow Futures

    27,148.00
    -260.00 (-0.95%)
     
  • Nasdaq Futures

    11,222.75
    -115.00 (-1.01%)
     
  • Russell 2000 Futures

    1,492.20
    -14.80 (-0.98%)
     
  • Crude Oil

    38.92
    -0.37 (-0.94%)
     
  • Gold

    1,888.90
    -14.30 (-0.75%)
     
  • Silver

    23.80
    -0.65 (-2.64%)
     
  • EUR/USD

    1.1705
    -0.0040 (-0.34%)
     
  • 10-Yr Bond

    0.6450
    0.0000 (0.00%)
     
  • Vix

    26.86
    +0.67 (+2.56%)
     
  • GBP/USD

    1.2832
    -0.0028 (-0.22%)
     
  • USD/JPY

    105.6500
    -0.0050 (-0.00%)
     
  • BTC-USD

    10,690.52
    -153.69 (-1.42%)
     
  • CMC Crypto 200

    219.96
    -9.71 (-4.23%)
     
  • FTSE 100

    5,885.39
    -12.11 (-0.21%)
     
  • Nikkei 225

    23,185.12
    -353.98 (-1.50%)
     

Insiders Roundup: Mastercard, ChemoCentryx

GuruFocus.com

The GuruFocus All-in-One Screener can be used to find insider trades from a specific period of time or for a certain range of values. For these stock picks, I went under the Insiders tab and changed the settings for All Insider Buying to "$2,000,000+," the duration to "July 2020" and All Insider Sales to "$2,000,000+."


According to these filters, the following are this past week's most significant trades from company insiders.

Nkarta

James E. Flynn, director and 10% owner Glaxosmithkline PLC (GSK) and 10% owners Novo Holdings A/S and RA Capital Management, L.P. bought 5.7 million shares of NKarta Inc. (NKTX) for an average price of $18 per share on July 14.

4b49c90735d71eeaded118f13ed28833.png
4b49c90735d71eeaded118f13ed28833.png

The biotechnology company has a market cap of $1.18 billion and an enterprise value of $1.09 billion.

The stock started to trade on July 16, and since than it hit a high price of $37.23 and a low price of $35.25.

WESCO International

Green Equity Investors VII, L., 10% owner of WESCO International Inc. (WCC), bought 962,805 shares for an average price of $35.78 per share on July 14.

fd1290ebb674082927ee129954f657ec.png
fd1290ebb674082927ee129954f657ec.png

The industrial distributor has a market cap of $2.10 billion and an enterprise value of $3.54 billion. It has insider ownership of 4.47% and institutional ownership of 64.46%.

Over the past 12 months, the stock has lost 16.93%. As of Friday, it was trading 31.65% below its 52-week high and 210.10% above its 52-week low.

Poseida

Directors Marcea Bland Lloyd and David Hirsch, together with director and 10% owner Sean Murphy, bought a combined 270,000 shares of Poseida Therapeutics Inc. (PSTX) for an average price of $16 per share on July 14.

b8cd632f0af2430a2638bd54576681c7.png
b8cd632f0af2430a2638bd54576681c7.png

The credit card manager has a market cap of $958 million and an enterprise value of $910 million.

Mastercard

Mastercard Foundation, 10% owner of Mastercard Inc. (MA), sold a combined 412,020 shares on July 13 and 16 for an average price of $297 per share.

6be3613425d36c525adb1c557eddc261.png
6be3613425d36c525adb1c557eddc261.png

The payment processor has a market cap of $300 billion and an enterprise value of $302 billion. It has insider ownership of 0.15% and institutional ownership of 54.55%.

Over the past 12 months, the stock has increased 8.22%. As of Friday, shares were trading 13.79% below the 52-week high and 49.68% above the 52-week low.

Salesforce.com

Marc Benioff, chair of the board and CEO of Salesforce.com Inc. (CRM), sold 30,000 shares for an average price of $186.71 per share on July 15 and 16.

809c31b738bd3ef517080f9af1f32852.png
809c31b738bd3ef517080f9af1f32852.png

The provider of cloud computing solutions has a market cap of $167 billion. It has insider ownership of 3.99% and institutional ownership of 64.19%.

Over the past 12 months, the stock has gained 18%. As of Friday, shares were trading 8.53% below the 52-week high and 60.91% above the 52-week low.

ChemoCentryx

Vifor (International) Ltd, 10% owner of ChemoCentryx Inc. (CCXI), sold a combined 505,642 shares for an average price of $58.17 per share on July 13 and 16.

53185ccdd36d82a39d418b61048492c9.png
53185ccdd36d82a39d418b61048492c9.png

The biopharmaceutical company has a market cap of $3.81 billion and an enterprise value of $3.65 billion. It has insider ownership of 4.61% and institutional ownership of 49.26%.

Over the past 12 months, the stock has climbed 578%. As of Friday, shares were trading 14.23% below the 52-week high and 811% above the 52-week low.

Disclosure: I do not own any stocks mentioned.

Read more here:



Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

This article first appeared on GuruFocus.